An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukaemia.

  • Flemming, Shaun (Primary Chief Investigator (PCI))
  • Wei, Andrew (Chief Investigator (CI))
  • Bajel, Ashish (Chief Investigator (CI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date20/10/20 → 31/12/25

Keywords

  • Malignant Haematology
  • Acute Myeloid Leukaemia (AML)
  • Clinical trial

Clinical Trial Phase

  • Phase I